Form 4: BioLife Solutions Director Acquires 5,701 Shares of Common Stock

Catherine Coste, a director of BioLife Solutions, acquired 5,701 shares of common stock on March 18, 2025, according to a Form 4 filing with the SEC.

Summary

• On March 18, 2025, Catherine Coste, a director of BioLife Solutions Inc. (BLFS), acquired 5,701 shares of common stock.
• The transaction was reported in a Form 4 filing with the Securities and Exchange Commission.
• The shares were acquired directly.
• The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan and fully vests on the first anniversary of the measurement date of 01-02-2025.

Sentiment

Score: 6

Explanation: Director's stock purchase is generally a mildly positive signal, suggesting confidence, but it's a single transaction and doesn't provide a comprehensive view of the company's financial health.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Director stock acquisitions are common and monitored by investors as an indicator of management's sentiment about the company's prospects. It's a routine part of corporate governance and insider trading regulations.

Stakeholder Impact

• The stock acquisition could have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

BioLife Solutions, BLFS, Catherine Coste, Form 4, SEC Filing, Stock Acquisition, Director, Common Stock, 2023 Performance Incentive Plan